humpath.com supports the 2014 edition of the European Symposium of Biopathology, June 19th and 20th 2014 in Paris, France.
Macroscopy, Microscopy, Videos, Digital slides, Virtual slides, Digital pathology, Biopathology, Molecular Pathology
Most recent articles
Olaparib is an inhibitor (PARP inhibitor) of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
Olaparib (AZD-2281) is an experimental chemotherapeutic agent, developed by KuDOS Pharmaceuticals and later by AstraZeneca, that is currently undergoing clinical trials.
It is an inhibitor of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which includes many ovarian, breast (...)
Ibrutinib is an inhibitor of the enzyme Bruton’s tyrosine kinase (BTK).
Ibrutinib (USAN, also known as PCI-32765 and marketed in the U.S. under the name Imbruvica) is an anticancer drug targeting B-cell malignancies. It was approved by the US FDA in November 2013 for the treatment of mantle cell lymphoma and in February 2014 for the treatment of chronic lymphocytic leukemia.
It is an orally-administered, selective and covalent inhibitor of the enzyme Bruton’s tyrosine kinase (BTK). (...)
Alectinib (Chugai, NDA has been filed in Japan) is an ALK inhibitor (WP).
Nivolumab, a drug in clinical trials also known as BMS-936558 or MDX1106, is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer.
Nivolumab acts as an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells.
Enzalutamide (marketed as Xtandi and formerly known as MDV3100) is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of metastatic castration-resistant prostate cancer.
Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine.
Early preclinical studies also suggest that enzalutamide inhibits breast cancer cell growth.
In August 2012, the U.S. Food and Drug (...)
06/24/2014 : New trends in Pathology Informatics http://www.european-hospital.com/en/article/11952.html
Blinatumomab (MT103) is a anti-CD19 drug that has anti-cancer properties. It belongs to a new class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells.
Blinatumomab specifically targets the CD19 antigen present on B cells.
The drug was developed by a German-American company Micromet, Inc. in cooperation with (...)
Usually affects head of epididymis
May be due to ischemia with secondary granulomatous reaction and scarring
In a histologic review of adult epididymides obtained at autopsy (both epididymides of 408 men) or during surgery (261 men with testicular or epididymal nontumoral pathology), a peculiar granulomatous lesion was observed in two autopsy specimens (unilateral) and three surgical specimens. (#9255259#)
The lesion is located in the caput epididymidis and consists of a zone of (...)
The goal of the SKY/M-FISH and CGH database is to provide a public platform for investigators to share and compare their molecular cytogenetic data. The database is open to everyone and all users can view an individual investigator’s public data or compare public cases from different investigators.
Those wishing to contribute their own data must register and can choose to keep their data private for a period not to exceed two (...)
previous page | next page